1.7 million for European research on lymphoma

1.7 million for European research on lymphoma

Pathologist Daphne de Jong of Amsterdam UMC has been awarded almost EUR 1.7 million by the prestigious European TRANSCAN program, together with teams from Germany, France and Austria, for their research proposal into a rare class of lymphoma. Via the Dutch Cancer Society KWF a total amount of EUR 400.000 will go to Amsterdam UMC. T-cell lymphoma is a rare type of lymphoma, which returns after treatment in most patients , or it does not disappear at all. Unfortunately, the survival rate for this type of lymphoma is very poor. Since T-cell lymphoma is rare, international collaboration is essential in order to achieve progress in the development of novel therapies.

"It is difficult to discover why the disease remains or returns despite treatment. There are no known biomarkers that can predict the disease, so there is no prospect of any new drugs or better treatments. We want to do something about this", says Daphne de Jong. Together with the other teams she will collect biopsy samples from patients with this lymphoma type from across Europe. This way a detailed genetic biomarker catalogue can be created and more insight in the development of these lymphomas is gained. The identification of novel biomarkers will allow the development of new treatments and drugs for peripheral T-cell lymphoma.